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Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. 
Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic 
loss of heterozygosity (LOH) patterns reminiscent of BRCA1 or BRCA2 mutant tumours. This raises the 
possibility that PARP inhibitors (PARPi), used to treat BRCA1/2 mutant cancers, could be used to target 
OS. Using high-throughput drug sensitivity screening we generated chemosensitivity profiles for 79 
small molecule inhibitors, including three clinical PARPi. Drug screening was performed in 88 tumour 
cell lines, including 18 OS TCLs. This identified known sensitivity effects in OS TCLs, such as sensitivity 
to FGFR inhibitors. When compared to BRCA1/2 mutant TCLs, OS TCLs, with the exception of LM7, 
were PARPi resistant, including those with previously determined BRCAness LoH profiles. Post-screen 
validation experiments confirmed PARPi sensitivity in LM7 cells as well as a defect in the ability to form 
nuclear RAD51 foci in response to DNA damage. LM7 provides one OS model for the study of PARPi 
sensitivity through a potential defect in RAD51-mediated DNA repair. The drug sensitivity dataset we 
generated in 88 TCLs could also serve as a resource for the study of drug sensitivity effects in OS.
Whilst there have been a number of successes in developing targeted approaches to carcinomas, for many patients 
diagnosed with hard to treat sarcomas, radical surgery and chemotherapy regimens still represent the standard 
of care, and survival rates have not significantly changed for some time. This is particularly true for patients 
diagnosed with osteosarcoma (OS), where there has been little improvement in overall survival in the past 20 
years, with five year survival remaining approximately 70% for young patients with localised disease1,2. For those 
with metastatic OS at diagnosis, outcome is worse, with only 20–30% surviving for more than five years3 and 
is even more dismal for those with recurrent disease4. There is a paucity of early phase clinical trials available 
for OS patients and therefore, new or repositioned agents are needed to improve the outcome of patients. With 
this in mind, recent work has suggested that a significant proportion of OS, perhaps as high as 80%, exhibit 
genomic features reminiscent of a ‘BRCAness’ phenotype5. BRCAness describes tumours that possess histopatho-
logical and molecular characteristics similar to those found in patients with germ-line BRCA1 or BRCA2 gene 
defects, including a distinctive DNA repair defect arising from loss of Homologous Recombination (HR) and 
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drug sensitivity effects associated with this HR defect, including exquisite PARP inhibitor sensitivity6. Using an 
analysis of whole-exome sequencing from 31 treatment naive osteosarcoma tumour samples, Kovac et al. identi-
fied large-scale genome instability signatures characteristic of BRCA1/2-deficient tumours and recurrent muta-
tions in tumour suppressor genes associated with homologous recombination and related DNA repair processes, 
including FANCA BRCA2 and ATM5. A subsequent analysis of OS tumour cell lines by Engert, Kovac et al.7 sug-
gested that two OS tumour cell line models (MG63 and ZK58) with genomic loss of heterozygosity characteristics 
somewhat reminiscent of BRCAness, exhibited sub-micromolar IC50 sensitivity to the clinical PARP inhibitor 
talazoparib (MG63 = 0.448 uM, ZK58 = 0.115 uM). However, whether the scale of PARP inhibitor sensitivity seen 
in OS models resembles that in BRCA gene mutant tumour cell lines was unclear.
Despite the need to identify novel targeted approaches in OS and the availability of a number of relatively 
well characterised tumour cell lines derived from these tumours, there is a limited amount of publically available 
information describing the small molecule sensitivity of these models. Such information could provide the start-
ing point for discovering novel treatment approaches for this particular sarcoma subtype. With this in mind, we 
describe here as a resource, a dataset detailing the chemosensitivity of 18 OS tumour cell lines, and an additional 
70 tumour cell lines derived from non-OS cancer histologies, to 79 small molecule inhibitors used in the treat-
ment of cancer or in late stage development. As part of this resource, we describe the sensitivity of OS tumour cell 
lines to three chemically distinct PARP inhibitors, comparing their sensitivity to BRCA1 mutant tumour cell lines 
and to a tumour cell line model with a CRISPR-Cas9 mutagenesis-engineered PARP inhibitor resistance-causing 
revertant mutation in BRCA1. We find that that the majority of OS tumour cell lines, with the exception of LM7, 
do not exhibit profound sensitivity to PARPi that might be associated with a BRCAness phenotype.
Results
Parallel chemosensitivity screens in OS and non-OS tumour cell lines. In order to generate a 
resource that could be used as a starting point to investigate sensitivity to targeted agents in OS, we compiled a 
panel of 18 well-characterised OS tumour cell lines (TCLs) and subjected these high-throughput drug sensitiv-
ity screening, alongside 70 tumour cell lines derived from the following carcinomas: breast (34) head and neck 
(11), synovial sarcoma (5), cervical (4), lung (4), large intestine (3), prostate (3), soft tissue (other than syno-
vial sarcoma) (3), haematopoietic (1), central nervous system (CNS) (1), and hepatic (1) (Fig. 1A and listed in 
Supplementary Table 1). Given the interest in PARP inhibitor sensitivity in OS, we also included in the tumour 
cell line panel a PARP inhibitor sensitive breast tumour cell line, SUM149, with loss of function BRCA1 mutation 
(BRCA1 p.P724fs*12) as well as a PARP inhibitor resistant SUM149-subclone, SUM149.B1*.S, that has partially 
restored BRCA1 function because of a CRISPR-Cas9 mutagenesis-engineered BRCA1 intragenic reversion muta-
tion8. This BRCA1 reversion mutation restores the native open reading frame of the BRCA1 gene, recapitulates 
RAD51 nuclear localisation (a key molecular event in BRCA1-mediated DNA repair) and causes profound PARP 
inhibitor resistance8.
For chemosensitivity screening, we used an in–house curated small molecule library of 79 small-molecule 
inhibitors that are either in clinical use for the treatment of cancer or in late-stage clinical development 
(Supplementary Table 2). To maximise the possibility of identifying chemosensitivity effects, each compound was 
included in the screening library at eight different concentrations. Tumour cell lines were plated in 384-well-plates 
and then 24 hours later exposed to library drugs; cells were then continuously cultured for a further five days 
in the presence of drug, at which point we estimated cell viability in each well by the use of CellTitreGlo rea-
gent. Each cell line was screened in triplicate and we combined data from replica screens in the final analysis. 
After processing the data from each plate to account for plate to plate variation across the library, we converted 
CellTitreGlo readings into: (i) surviving fraction (SF) data for triplicate drug sensitivity screens in 88 tumour 
cell lines (Supplementary Table 3); (ii) unscaled area under the curve (Supplementary Table 4); (iii) scaled AUC 
scores calculated as in9 (Supplementary Table 5); and (iv) a Z score normalised version of the unscaled AUC 
values (Supplementary Table 6 and Supplementary Figure 1A,B). These datasets, provided as a resource in the 
Supplementary Tables, allowed us to compare drug sensitivity effects between different tumour cell lines.
Prior to assessing the drug sensitivity effects in tumour cell lines, we first assessed the reproducibility of replica 
screens and the dynamic range found in each individual screen. We estimated the reproducibility of triplicate 
screens in each cell line by calculating Pearson’s correlation values between replicas and estimated dynamic range 
by calculating Z′ values for each screen (Fig. 1C,D). For the final resource (Fig. 1E, Supplementary Tables), we 
only included data where Pearson’s correlation values between replicas were >0.7 and median Z′ values were >0.3 
(Fig. 1C,D).
Drug sensitivity effects in OS tumour cell lines. Amplification of the Fibroblast Growth Factor 
Receptor 1 (FGFR1) gene in OS tumour cell lines has previously been shown to predict enhanced sensitivity to 
FGFR inhibition by the pan-FGFR inhibitor NVP-BGJ39810. To assess the ability of our screen data to identify 
this known chemosensitivity effect, we interrogated the screen data from OS tumour cell lines for two different 
FGFR inhibitors, AZ4547 and PD173074. We noted that, in general, OS TCLs exhibited greater sensitivity to 
AZD4547 (Fig. 1F, p = 0.01, Mann-Whitney uncorrected test), as previously noted11 and found that AZ4547 vs. 
PD173074 sensitivities in OS TCLs were highly correlated (Fig. 1G, Spearman’s r = 0.96, p < 0.0001, uncorrected 
test). We also found that OS tumour cell lines with FGFR1 amplification (G292, NOS1 and CAL72) or FGFR1 
gain (HU09 and NY) were significantly more sensitive to both AZ547 and PD173074 than those OS tumour cell 
lines without FGFR1 copy number alterations (Fig. 1H,I, p < 0.01 in both cases, Mann-Whitney uncorrected 
test and Fig. 1J,K). Similarly, we noticed that, as for other cancer histotypes12, RB1 (Retinoblastoma) tumour 
suppressor defects in OS TCLs (Supplementary Table 711 were associated with resistance to the CDK4,6 inhibitor, 
palbociclib (Fig. 1L, p 0.031, Mann-Whitney uncorrected test), suggesting that genotype-specific drug sensitivity 
effects in OS TCLs could be identified.
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Figure 1. Drug screening overview. (A) Schematic of high-throughput small molecule chemosensitivity screens. 
Tumour cell lines (TCLs) were plated in 384-well plates in log phase and exposed to small molecule inhibitors for 
five continuous days, at which point cell viability was estimated by use of CellTitreGlo reagent (CTG). (B) Piechart 
illustrating the histotypes of the 88 tumour cell lines included in the study. (C) Scatter plot of Pearson’s correlation 
values between triplicate screens. Only tumour cell lines that had Pearson’s correlation values between triplicate 
screens of >0.7 were included in the final dataset. Median and range shown. (D) Scatter plot of Z prime values for 
each replica of the screen. Only tumour cell lines that had median Z prime values of >0.3 were included in the final 
dataset. Median and range shown. (E) Heatmap illustrating Area Under the Curve (AUC) values for each drug in 
each tumour cell line. Heatmaps illustrating the dataset described as scaled AUC scores and unscaled AUC Z scores 
are show in Supplementary Figure 1. (F) Box whiskers plot of AZD4547 FGFR inhibitor AUC Z scores in 88 tumour 
cell lines, illustrating the relative sensitivity of OS TCLs. p value 0.0102, Mann-Whitney test. (G) Scatter plot of 
AZD4547 FGFR inhibitor AUC Z scores in OS TCLs, compared to AUC Z scores for the FGFR inhibitor PD173074. 
(H) Box whiskers plot of AZD4547 FGFR inhibitor AUC Z scores in OS tumour cell lines classified according to 
FGFR1 gene status. p value 0.0044, Mann-Whitney test. (I) Box whiskers plot of PD173074 FGFR inhibitor AUC Z 
scores in OS tumour cell lines classified according to FGFR1 gene status. p value 0.0098, Mann-Whitney test.  
www.nature.com/scientificreports/
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PARP inhibitor sensitivity in OS tumour cell lines. Based on these proof of concept examples, we inter-
rogated the dataset to examine the sensitivity of OS TCLs to PARP inhibitors. Recent analysis of exome DNA 
resequencing data from treatment naïve OS has suggested that a significant fraction of OS might exhibit a pattern 
of chromosomal aberrations, specifically chromosomal loss of heterozygosity (LOH) effects, that are somewhat 
reminiscent of mutational patterns seen in tumours from cancer patients with germ-line BRCA1 or BRCA2 gene 
mutations5. These characteristics of BRCAness might have therapeutic implications, as the DNA repair defects 
thought to lead to this particular type of LOH effect, can often cause sensitivity to PARPi.
To estimate the relative PARPi sensitivity of OS (and other histology) TCLs, we extracted from the dataset the 
AUC Z scores for three clinical PARP inhibitors; rucaparib, olaparib and talazoparib. When we compared the sen-
sitivity profiles of TCLs to the three different PARP inhibitors, we found these to be highly correlated (Fig. 2A–C). 
When assessing the relative sensitivity of cell line models from different cancer histologies, we found that in 
general, breast tumour cell lines and also synovial sarcoma tumour cell lines displayed the greatest level of PARP 
inhibitor sensitivity (Fig. 2D). Indeed, synovial sarcoma TCLs not only showed PARP inhibitor sensitivity, as 
previously described13, but also enhanced sensitivity to the DNA damaging agents doxorubicin, gemcitabine and 
camptothecin (Supplementary Figure 1). As positive and negative controls respectively, we included in the screen 
BRCA1 mutant, PARPi sensitive SUM149 cells and a PARPi resistant SUM149 subclone with a BRCA1 reversion 
mutation, described elsewhere8. As expected, we found SUM149 cells to display one of the most profound PARP 
inhibitor sensitivity effects in the panel of 92 tumour cell lines (ranked 3rd, 2nd, and 5th for olaparib, talazoparib 
and rucaparib sensitivity respectively, Fig. 2E–G), whereas the SUM149 BRCA1 revertant tumour clone displayed 
profound PARPi resistance (Fig. 2E–G). We also noted additional BRCA1 mutant tumour cell lines (MDAMB436, 
HCC1395) and a BRCA1 promoter hypermethylated tumour cell line HCC3814 to display PARPi sensitivity, as did 
a number of synovial sarcoma tumour cell lines (SYO1, CME, HS-SYII, ASKA), as described earlier (Fig. 2E–G).
OS TCLs demonstrated a spectrum of PARPi sensitivity effects (Fig. 2E–G). Out of 18 OS tumour cell 
lines assessed, only LM7 demonstrated profound sensitivity to PARPi of a scale similar to that seen in BRCA1 
mutant SUM149 cells (Fig. 2E–G). LM7 cells were originally derived from SAOS2 cells by repeated passage of 
SAOS2 through the lungs of nude mice15. We found SAOS2 cells to be relatively resistant to all three PARPi, 
when compared to LM7 (Fig. 2E–G), suggesting that heightened PARPi sensitivity in LM7 was an acquired phe-
notype. We also assessed the PARPi sensitivity of OS TCLs proposed to have genomic signatures indicative of 
BRCAness; MG63, SAOS2, and HOSMNNG7. We found each of these TCLs to be relatively resistant to PARPi, 
when compared to SUM149 cells (median AUC for olaparib, Rucaparib and Talazoparib for MG63, SAOS2, and 
HOSMNNG being 0.985, 0.896, 0.967, compared to 0.722 in SUM149) and to display a similar level of PARPi 
resistance as the BRCA1 revertant SUM149 subclone (Fig. 2E–G).
To investigate the PARPi sensitivity phenotype of LM7 cells in more detail, we used two-week clonogenic 
drug exposure assays to confirm the results identified in the screen. Although exome sequencing of LM7 
cells did not identify BRCA1 nor BRCA2 gene alterations, LM7 cells exhibited comparable olaparib sensitiv-
ity to BRCA2 defective (BRCA2 c.6774delT truncating mutant) CAPAN1 pancreatic ductal carcinoma cells16 
(ANOVA p = 0.3757) but significantly greater sensitivity to olaparib than BRCA1 mutant SUM149 cells (ANOVA 
p = 0.0119), the BRCA1 revertant SUM149 subclone, and a previously validated PARPi resistant BRCA2 revertant 
CAPAN1 subclone, CAPAN1.B2*.S8 (ANOVA p < 0.0001, Fig. 3A,B). LM7 cells also exhibited similar sensitivity 
to Talazoparib, demonstrating significantly greater sensitivity to this PARPi than CAPAN1.B2*.S and SUM149.
B1*.S (ANOVA p < 0.001, Fig. 3C,D).
LM7 cells exhibit defects in RAD51 and other proteins associated with homologous recombination. 
The nuclear localisation of the DNA recombinase RAD51 to the site of DNA damage is a key step in the DNA repair 
processes mediated by BRCA1 and BRCA2 and is critical in repairing the DNA lesions caused by PARP inhibi-
tors. This nuclear localisation of RAD51 can be estimated by microscopy-based imaging of discrete nuclear RAD51 
foci17. We investigated whether LM7 cells exhibited a RAD51 nuclear localisation defect, finding that in response to 
DNA damage, LM7 cells exhibited significantly decreased nuclear RAD51 foci formation, compared to SAOS2 cells 
(p = 0.0005, Student’s t test, Fig. 3E), an observation consistent with their PARPi sensitivity (Fig. 3A–D). Although 
we were not able to detect DNA mutations in genes known to control PARPi sensitivity in LM7 cells (data not 
shown) proteomic profiling of SAOS2 and LM7 cells identified differentially expressed proteins that might explain 
the PARPi sensitivity phenotype in LM7 cells (Supplementary Table 8); in totality, we identified 26 proteins that 
were overexpressed in LM7 compared to SAOS2 and 80 proteins that were under expressed in LM7 (Fig. 3F). These 
included two proteins previously linked to DNA repair by homologous recombination; RAD54L2 (ranked 2nd most 
under expressed in LM7 vs. SAOS2, p = 0.01, two sided heteroscedastic t-test) and RECQL418 (ranked 13th most 
under expressed in LM7 tumour cells, p = 0.019, two sided heteroscedastic t-test).
Discussion
We describe here chemosensitivity profiles for a panel of OS tumour cell lines. Our intention in carrying out 
this work was to generate a reference dataset that could be used for a variety of applications, ranging from the 
selection of tumour cell models with defined drug sensitivity/resistance phenotypes for subsequent experiments, 
through to the identification of drug sensitivity effects associated with molecular features found in these diseases. 
(J,K) Example dose response survival curves derived from screen data for FGFR inhibitors in two OS TCLs, G292 
(FGFR1 amplified) and SAOS2 (FGFR1 copy number neutral). (L) Box whiskers plot of Palbociclib CDK4/6 
inhibitor AUC Z scores in OS tumour cell lines classified according to Rb status. p value 0.0031, Mann-Whitney test. 
(M) Example dose response survival curves derived from screen data for palbociclib in two OS TCLs, CAL72 (Rb 
defective) and SAOS2 (Rb not altered).
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Figure 2. PARP inhibitor sensitivity in tumour cell lines determined by the chemosensitivity screen.  
(A–C) Scatter plots illustrating the correlation in AUC Z scores for three different PARP inhibitors (rucaparib, 
talazoparib, olaparib) in 88 tumour cell lines. For each plot, the Spearman’s correlation coefficient, r, is shown. 
(D) Scatter plots illustrating AUC Z scores for rucaparib, talazoparib and olaparib classified according to 
tumour cell line histotype. Each dot represents a single TCL; error bars represent mean and standard error of 
the mean. (E–G) Waterfall plot illustrating olaparib (E), talazoparib (F) and rucaparib (G) AUC Z scores in 88 
TCLs. Breast tumour cell lines with BRCA1 alterations are shown, as is the PARP inhibitor resistant/BRCA1 
revertant SUM149-subclone (“SUM149 with BRCA1 reversion”, see main text). Red dots indicate OS tumour 
cell lines, blue dots indicate non-OS TCLs.
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Figure 3. PARP inhibitor sensitivity and RAD51 defects in OS tumour cell lines. (A) Olaparib dose response 
curves derived from clonogenic assays where TCLs were exposed to PARP inhibitor for 14 continuous days. 
LM7 and SAOS2 cells were compared to CAPAN1 cells (BRCA2 mutant, PARP inhibitor sensitive), CAPAN1.
B2*.S (BRCA2 revertant, PARP inhibitor resistant), SUM149 (BRCA1 mutant, PARP inhibitor sensitive) and 
SUM149.B1*.S (BRCA1 revertant, PARP inhibitor resistant) cells. Error bars represent SEM from triplicate 
experiments. (B) Table illustrating ANOVA p values from olaparib sensitivity comparisons in (A). (C,D) 
Talazoparib dose response curves and ANOVA p values derived from clonogenic assays where TCLs were 
exposed to PARP inhibitor for 14 continuous days. As for (A,B) (E) Bar chart illustrating the quantitation of 
nuclear RAD51 foci in tumour cells after exposure to ionising radiation. Cells were plated in triplicate in 6-well 
plates on coverslips. After 24 hours, tumour cells were irradiated (10 Gy) and cultured for a subsequent four 
hours, at which point cells were fixed and immunostained. Confocal microscopy was used to visualise and 
score nuclear γH2AX and RAD51 foci. Cells containing more than five nuclear foci were considered positive. 
Mean ± SEM for three independent experiments are shown. LM7 cells exhibited significantly decreased nuclear 
RAD51 foci formation compared to SAOS2 (p = 0.0005). p values were calculated using Student’s t test.  
(F) Differential protein levels in SAOS2 and LM7 cells. Schematic of experimental procedure used to determine 
proteomic profiles in LM7 and parental SAOS2 cells is shown left. Following lysis, protein purification, and 
tryptic digest, peptides were separated by liquid chromatography and measured by mass spectrometer. Label-
free proteome quantification was performed using the MaxQuant software environment to determine the 
quantitative abundance of 6696 peptides with a false discovery rate of less than one percent. Volcano plot of 
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Given the “resource” nature of the work, we have included within this report, both raw and processed data so that 
subsequent analyses can be facilitated. For example, as the molecular profiling of these tumour cell line models is 
enhanced, for example by the addition of proteomic profiles of OS tumour cell lines, the utility of the chemosen-
sitivity profiles we describe here will no doubt be enhanced.
As part of this work, we highlight how the dataset can be used to assess PARP inhibitor sensitivity in OS 
tumour cell lines. By comparing the PARP inhibitor sensitivity of OS tumour cell lines to the scale of sensitivity 
in breast tumour cell lines with BRCA1 defects and also isogenic tumour cell models with a well-established and 
clinically relevant mechanism of PARP inhibitor resistance, we have been able to make a comparative analysis that 
suggests that whilst most OS tumour cell lines do not exhibit the exquisite level of PARP inhibitor sensitivity seen 
in BRCA1 mutant breast tumour cell lines, the LM7 model does display evidence of BRCAness and a PARP inhib-
itor sensitivity phenotype. Although this is a singular model, the LM7 cell line therefore does provide a reagent 
for investigating mechanisms that cause PARP inhibitor sensitivity in OS.
It is important to describe the limitations of the resource we provide. Using three-dimensional tissue culture 
approaches would assess whether the drug sensitivity and resistance phenotypes we see here are robust in the face 
of the loss of an adherent surface or changes in cell morphology and organisation often more apparent in three 
dimensional, as opposed to two-dimensional culture systems. We also note that more prolonged drug exposures, 
beyond the five-day drug exposure used here, might also elicit distinct effects, especially for agents whose cell 
inhibitory properties are amplified by drug exposure over multiple cell cycles. Nevertheless, we did find that the 
five-day drug exposure used was sufficient to document differences in PARP inhibitor sensitivity between BRCA1 
mutant and BRCA1 revertant clones; the synthetic lethal effects of PARP inhibitors in in vitro cell culture often 
require drug exposure over several cell cycles (Farmer et al., 2005), but the five-day exposure appears sufficient 
here.
Materials and Methods
Cell lines. The origin of non-OS tumour cell lines is described in (Campbell et al., 2016; Jones et al., 2017). 
For OS tumour cell lines, G292 (clone A141B1), MG63, CAL72, HU03N1, OSA/SJSA-1, NOS1, SAOS2, U2OS, 
HU09, NY and HOS were gifts from Ultan McDermott at the Wellcome Trust Sanger Institute (WTSI); LM7, 
OHSN, OSH25HAL (HAL) MHM, and KPD were gifts from Ola Myklebost, Univeristy of Bergen, Norway. 
Head and neck cancer cell line models were obtained from Susanne Gollin and Theresa Whiteside (University of 
Pittsburgh), Tom Carey (University of Michigan) and Hans Joenje (VU Medical Centre, NL). All cell lines were 
maintained as per the suppliers’ instructions. STR typing of 10 loci was performed on each cell line using the 
GenePrint 10 system (Promega) and used to confirm the identity of cell lines prior to storage.
Small molecule inhibitor high-throughput screens. Small molecules were purchased as solid from 
suppliers listed in Supplementary Table 2 and stored in DMSO. Prior to 384 well-plate screens, solid small mol-
ecules were resuspended in DMSO as 10 mM stocks, prior to further dilution in DMSO to create 384 well-plates 
containing a titration (0.5, 1, 5, 10, 50, 100, 500, 1000 nM). A Hamilton Microlab Star liquid handling platform 
was used for this and all subsequent liquid handling steps with the exception of cell seeding.
Cells growing in log phase were seeded in 384 well-plates at 250–500 cells per well in 50 uL of tissue culture 
media using a Thermo Fisher Multi-Drop Combi. Cells were initially plated at a density to ensure that each cell 
line was in growth phase by the end of the five-day treatment, similar to19. 24 hours after seeding, media was 
removed and changed to media containing the small molecule inhibitor library, as detailed above. Cells were then 
continuously cultured in the presence of small molecule inhibitors for a period of five days, at which point cell 
viability was estimated by adding 20 uL (diluted 1/4 in PBS) Cell-Titre Glo (Promega) to media. After 10 minutes 
incubation at room temperature, Cell-Titre Glo generated luminescence was captured using a Victor X-Light 
plate reader. Luminescence values from each well were normalised to the median of signals from wells exposed to 
DMSO only (no small molecule inhibitor) to generate surviving fractions (SF). In total, each tumour cell line was 
screened three times, generating triplicate SF data sets (Supplementary Table 3). Surviving fractions were then 
used to plot dose-response survival curves, generated using 3-parameter logistic regression analysis via the drc 
R-package20. Using drc, Area under the curve (AUC) values were calculated from dose-response survival curves 
(Supplementary Table 4, unscaled AUC scores for 88 tumour cell lines). These unscaled AUC values (calculated as 
per Activity Area Aref = 0 values in9 were then scaled according to Aref = max (0, Alow) (as9) where Alow is the activ-
ity at the lowest concentration of drug used, up to the maximum tested concentration (Supplementary Table 5, 
scaled AUC scores for 88 tumour cell lines). Unscaled AUC values for each drug in 88 tumour cell lines were also 
standardized, generating robust Z scores based upon the median AUC effect in all 88 tumour cell lines and the 
median absolute mediation of these effects (Supplementary Table 5 – Z normalised unscaled AUC scores for 88 
tumour cell lines). To compare drug sensitivities to FGFR1 status in OS TCLs, the cBioPortal was used to access 
Comparative Genomic Hybridisation (CGH) data for OS TCLs from the Broad Institute CCLE, scored via the 
GISTIC algorithm to define amplification (score +2) of FGFR1. Rb status (Supplementary Table 7) in OS TCLs 
from11 was used to assess the correlation between Rb status and palbociclib sensitivity. PARP inhibitor sensitivity 
effects identified in the high-throughput screen were confirmed using clonogenic survival assays, performed as 
described in21.
median difference in proteomic abundance between LM7 and SAOS2 shown right. RAD54L2 and RECQL4 
are highlighted. Only peptides with a significant difference in abundance between LM7 and SAOS2 are shown 
(p < 0.05 effects (two sided heteroscedastic t-test) with an absolute difference in log2(LFQ) greater than 3).
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Confocal microscopy. Nuclear RAD51 foci were visualised and quantified by immunohistochemistry as 
described previously8.
Proteomic profiling. Proteomic abundance for the osteosarcoma tumour cell lines was performed as fol-
lows: Following lysis, protein purification, and tryptic digest, peptides were separated by liquid chromatography 
and measured mass spectrometer. Label-free proteome quantification was performed using the MaxQuant soft-
ware environment22,23 to determine the quantitative abundance of 6696 peptides with a false discovery rate of less 
than one percent. Log2 transformed label free quantification (LFQ) values were used for all analyses. Proteins 
were identified as differentially expressed if they were associated with a p < 0.05 effect (two sided heteroscedastic 
t-test) and an absolute difference in log2(LFQ) greater than 3.
Data availability. All processed data is present in Supplementary Tables 1–8. Raw luminescence data from 
the chemosensitivity screen is available upon request.
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